Please use this identifier to cite or link to this item: https://doi.org/10.1038/srep24786
DC FieldValue
dc.titleKIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer
dc.contributor.authorLiu, Y.-Z
dc.contributor.authorYang, H
dc.contributor.authorCao, J
dc.contributor.authorJiang, Y.-Y
dc.contributor.authorHao, J.-J
dc.contributor.authorXu, X
dc.contributor.authorCai, Y
dc.contributor.authorWang, M.-R
dc.date.accessioned2020-10-22T03:01:02Z
dc.date.available2020-10-22T03:01:02Z
dc.date.issued2016
dc.identifier.citationLiu, Y.-Z, Yang, H, Cao, J, Jiang, Y.-Y, Hao, J.-J, Xu, X, Cai, Y, Wang, M.-R (2016). KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer. Scientific Reports 6 : 24786. ScholarBank@NUS Repository. https://doi.org/10.1038/srep24786
dc.identifier.issn20452322
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/178917
dc.description.abstractNowadays, no robust biomarkers have been applied to clinical practice to provide prognostic evaluation of non-small cell lung cancer (NSCLC). This study aims to identify new potential prognostic biomarkers for NSCLC. In the present work, KIAA1522 is screened out from two independent GEO datasets as aberrantly up-regulated gene in NSCLC tissues. We evaluate KIAA1522 expression immunohistochemically in 583 NSCLC tissue samples and paired non-tumor tissues. KIAA1522 displays stronger staining in NSCLC cases than in adjacent normal lung tissues. Importantly, patients with KIAA1522 overexpression had a significantly shorter overall survival compared to those with low expression (P < 0.00001). Multivariate Cox regression analyses show that KIAA1522 is an independent prognostic indicator, even for early-stage NSCLCs (P = 0.00025, HR = 2.317, 95%CI: 1.477-3.635). We also found that high expression of KIAA1522 is a significant risk factor for decreased overall survival of the patients who received platinum-based chemotherapy. Gene set enrichment analysis (GSEA) and functional studies reveal that KIAA1522 is associated with oncogenic KRAS pathways. Taken together, high expression of KIAA1522 can be used as an independent biomarker for predication of poor survival and platinum-resistance of NSCLC patients, and aberrant KIAA1522 might be a new target for the therapy of the disease.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectantineoplastic agent
dc.subjectKRAS protein, human
dc.subjectmessenger RNA
dc.subjectprotein p21
dc.subjecttumor marker
dc.subjectadult
dc.subjectaged
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectfemale
dc.subjectgene expression regulation
dc.subjectgenetics
dc.subjecthuman
dc.subjectKaplan Meier method
dc.subjectlung tumor
dc.subjectmale
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectprognosis
dc.subjectproportional hazards model
dc.subjectsignal transduction
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAged
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBiomarkers, Tumor
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectFemale
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectKaplan-Meier Estimate
dc.subjectLung Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectProportional Hazards Models
dc.subjectProto-Oncogene Proteins p21(ras)
dc.subjectRNA, Messenger
dc.subjectSignal Transduction
dc.subjectTreatment Outcome
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.1038/srep24786
dc.description.sourcetitleScientific Reports
dc.description.volume6
dc.description.page24786
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_srep24786.pdf6.2 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

11
checked on Apr 19, 2021

Page view(s)

40
checked on Apr 16, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons